Adam Marsh, Ph.D., is Chief Science Officer and co-Founder of Genome Profiling LLC. He is also a faculty member in the Center for Bioinformatics and Computational Biology at the University of Delaware. His academic research efforts 15 years ago were focused on epigenetics of environmental imprinting in animals living in extreme environments (polar seas, deep oceans) which lead to the development of a novel and robust software platform for quantifying and profiling DNA methylation from NGS data. As CSO of Genome Profiling LLC , he oversees the application of this platform to help clinical researchers and biopharma partners discover epigenetic biomarkers for drug response stratification and predicting, diagnosing and improving therapeutic efficacy for patients with chronic and life threatening diseases. Dr. Marsh received his Ph.D. from the University of Maryland, College Park, and pursued postdoctoral research in cell biology (Univ. New Hampshire, Durham), molecular biology and invertebrate immunology (Center of Marine Biotechnology, Univ. Maryland, Baltimore), and molecular physiology (Univ. Southern California, Los Angeles). Across all phases of his career computer programming, biostatistics and big-data have played a large role in defining his research vision and goals.